Manages renal tubular acidosis. ANDA 214420, held by Ascent Pharms Inc. Potassium Citrate.
As of Nov 16, 2026, ANDA 214420 (Potassium Citrate), held by Ascent Pharms Inc, was first approved by FDA on Feb 5, 2021, with 1 approved supplement and 0 published complete response letters.
Potassium citrate extended-release tablets are a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones Hypocitraturic calcium oxalate nephrolithiasis of any etiology Uric acid lithiasis with or without calcium stones 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2021 | Original application | Approved | None posted |
| Potassium Citrate5MEQ · tablet, extended release;oral | Potassium Citrate | Rx |
| Potassium Citrate10MEQ · tablet, extended release;oral | Potassium Citrate | Rx |
| Potassium Citrate15MEQ · tablet, extended release;oral | Potassium Citrate | Rx |
| Mar 31, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 5, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters